Akums Drugs and Pharmaceuticals Limited

CLOSED

IPO Date: 30 Jul - 1 Aug 2024

Listing Date: 6 Aug 2024

Price Range

646 to 679

Issue Size

1856.74 Cr

Min Investment

14,212

Lot Size

22 Shares

Schedule of Akums Drugs and Pharmaceuticals Limited

Issue open date

30 Jul 2024

Issue close date

1 Aug 2024

UPI mandate deadline

1 Aug 2024 (5 PM)

Allotment finalization

2 Aug 2024

Share credit

5 Aug 2024

Listing date

6 Aug 2024

Mandate end date

16 Aug 2024

Issue size

Funds Raised in the IPOAmount
Overall1856.74 Cr
Fresh Issue0 Cr
Offer for Sale0 Cr

Allotment DetailsNew

Allotment TimelineDetails
Allotment Date2 Aug 2024
Allotment Link{Link}

Grey Market PremiumNew

Grey Market Premium (GMP) is the premium at which the shares are traded in the grey market. It gives a fair idea about the listing price of the IPO shares. The GMP can be positive or negative based on the demand and supply of the shares in the grey market.

DateIpo PriceGMPEstimated Listing Price
6 Aug 202467943722 (6.33%)
5 Aug 202467943722 (6.33%)
4 Aug 202467986765 (12.67%)
3 Aug 202467999778 (14.58%)
2 Aug 2024679124803 (18.26%)
1 Aug 2024679141820 (20.77%)
31 Jul 2024679170849 (25.04%)
30 Jul 2024679177856 (26.07%)
29 Jul 2024679211890 (31.08%)
28 Jul 2024679180859 (26.51%)
27 Jul 2024679170849 (25.04%)

Performance Akums Drugs and Pharmaceuticals Limited

Issue PriceListing GainCurrent Market PriceP/L
646 to 679 6084 (17.27%) 503.6-25.83%

About Akums Drugs and Pharmaceuticals Limited

Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. The company primarily provides end-to-end solutions for product development and manufacturing as well as research and development (R&D) of formulations, preparation and submission of regulatory dossiers in the Indian and global markets and other testing services. The company is also engaged in the manufacture and sale of branded drugs and active pharmaceutical ingredients (APIs). As a CDMO, the company manufactures a wide range of dosage forms including tablets, capsules, liquid medicines, vials, ampoules, blow-filled closures, topical preparations, eye drops, dry powder injections and gummy bears, to name a few. The company has produced a total of 4,025 commercialized formulations in over 60 dosage forms. In the financial year 2023, the company manufactured formulations for 26 of the top 30 pharmaceutical companies in India in terms of revenue. For its CDMO business, the company operates 10 manufacturing units with a cumulative production capacity of 49.21 billion units annually (as of September 30, 2023). The company plans to expand its production capacity with two additional production units for its CDMO business to be commissioned in FY 2025. Some of its production facilities have been accredited by various global regulatory bodies such as the European Good Manufacturing Practice (EU-GMP), the World Health Organization Good Manufacturing Practice (WHO-GMP) and the United States National Sanitation Foundation (US NSF). As of September 30, 2023, Akums Drugs and Pharmaceuticals had a total of 16,463 employees, including 7,211 full-time employees and 9,252 contract employees.

Founded in2004
Managing director
Parent organization

Financial Overview

Strengths

    Risks

      Subscription Figures

      CategorySubscription (No. of times)
      Qualified Institutional Buyers (QIBs)90.09
      Non-Institutional Investors (NIIs)42.1
      Retail Individual Investors (RIIs)20.8
      Employee4.14
      Total63.44